RIPK2 inhibition gets the NOD for asthma

IF 16.6 1区医学 Q1 RESPIRATORY SYSTEM

European Respiratory Journal Pub Date : 2024-10-03 DOI:10.1183/13993003.01372-2024

Henry J. McSorley

引用次数: 0

Abstract

Extract

Asthma is a common disease affecting around 300 million people worldwide [1]. It is associated with airway remodelling, smooth muscle hypercontractility and increased mucus production, all of which can cause reduced lung function, reversible airway obstruction and characteristic wheeze.

查看原文本刊更多论文

抑制 RIPK2 可获得治疗哮喘的 NOD

提取物哮喘是一种常见疾病，影响着全球约 3 亿人[1]。它与气道重塑、平滑肌收缩力亢进和粘液分泌增加有关，所有这些都会导致肺功能下降、可逆性气道阻塞和特征性喘息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Respiratory Journal 医学-呼吸系统

CiteScore

27.50

自引率

3.30%

发文量

345

审稿时长

2-4 weeks

期刊介绍： The European Respiratory Journal (ERJ) is the flagship journal of the European Respiratory Society. It has a current impact factor of 24.9. The journal covers various aspects of adult and paediatric respiratory medicine, including cell biology, epidemiology, immunology, oncology, pathophysiology, imaging, occupational medicine, intensive care, sleep medicine, and thoracic surgery. In addition to original research material, the ERJ publishes editorial commentaries, reviews, short research letters, and correspondence to the editor. The articles are published continuously and collected into 12 monthly issues in two volumes per year.